Advanced searches left 3/3

Sumatriptan - DOAJ

Summarized by Plex Scholar
Last Updated: 02 August 2022

* If you want to update the article please login/register

Protective Effects of Lithium on Sumatriptan-Induced Memory Impairment in Mice

Sumatriptan is a 5-HT1B/1D receptor agonist used for the treatment of cluster headaches and migraine, and it may cause memory loss as a potential side effect. In a Y-maze test, lithium and sumatriptan were tested on memory acquisition, and lithium and sumatriptan were assessed on memory acquisition, followed by lithium and sumatriptan in a passive avoidance analysis. In both of the experiments, lithium's effects on sumatriptan-induced memory loss were investigated. In both experiments, Lithium had no effect on memory performance relative to a saline-treated control group, but sumatriptan-induced memory impairment in Y-maze and passive avoidance tests had been significantly different, but sumatriptan-induced memory impairment in Y-maze and passive avoidance tests had no effect on memory function, but sumatriptan-induced memory impairment in both tests was much greater.

Source link: https://doaj.org/article/3558bb9550534aaabdcd04f5a4e72d7e


Signal amplification for sumatriptan sensing based on polymeric surface decorated with Cu nanoparticles

On the new electrode, the electron transfer characteristics of the drug sumatriptan was greatly enhanced. The prepared electrode was used for the precise determination of SUM by differential pulse voltammetry, which was used in the sensitive determination of SUM. In the concentration ranges of 0. 08 u20130. 58 and 0. 58 u20136. 5 u03bcM, with a detection limit of 0. 025 bcM, a linear calibration curve was established.

Source link: https://doi.org/10.2298/JSC170727006K


Nitroglycerin enhances the propagation of cortical spreading depression: comparative studies with sumatriptan and novel kynurenic acid analogues

Although evidence on drug effectiveness in these models is often lacking, we're exploring a new integrated migraine system in which an effective pharmacon could be more easily identified. Methods and methods: In vivo electrophysiological experiments were conducted to see the effects of nitroglycerin on CSD caused by KCl use. Results: Following the NTG's, the basic parameters of CSDs remained unchanged; however, dissemination was reduced relative to the controls; Sumatriptan reduced the number of CSDs, although replication failure was as poor as in the NTG group. On the other hand, both of the KYNA analogues restored the ratio of propagation to the control level. Discussion: The percentage of propagation seemed to be a predictor of NTG's effect. This is the first report containing concrete evidence that NTG influences CSD; in addition, we observed the different effects of sumatriptan and KYNA analogues.

Source link: https://doaj.org/article/9135999170d042749f648441c8812f97


Preparation and characterization of timed drug delivery system of sumatriptan using natural polymers

Pulsatile drug delivery systems are time-controlled dosing systems that are designed to introduce the active pharmaceutical component after a predetermined lag time in order to synchronize the disease circadian rhythm. Sumatriptan, a selective agonist of serotonin receptors, is an effective treatment for acute migraine attacks. A migraine displays circadian rhythm with a significant rise in attacks between 6 a m. and 8 a m. Different amounts of natural and synthetic polymers were used in the manufacture of press-coated tablets, including: six formulas of fast dissolving core tablets and three formulations of press-coated tablets, were prepared by direct compression technology with different variables.

Source link: https://doi.org/10.31351/vol27iss1pp89-99


Efficacy of Sumatriptan/Placebo versus Sumatriptan/Propofol Combination in Acute Migraine; a Randomized Clinical Trial

Migraine headaches can cause significant pain for patients and can lead to multiple visits to the emergency department. This research sought to determine the safety of propofol + sumatriptan combination in comparison to sumatriptan alone in the treatment of acute migraine headaches. Methods: Patients who referred to two emergency departments with acute migraine headaches were referred to two clinical centers in this triple-blind trial. The mean pain score reduction in the intervention group was significantly higher than that in the control group after 30 and 60 minutes from the start of therapy. The absolute risk reduction of adverse events in patients with acute migraine headaches requiring propofol and sumatriptan therapy was 32. 8 percent. Conclusions: This research backs up the use of propofol for acute migraine headache relief, and it finds that combining sumatriptan with propofol is more efficient in relieving migraine headaches and the associated symptoms than using sumatriptan alone.

Source link: https://doi.org/10.22037/aaem.v10i1.1510


Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs

Patients undergoing a migraine attack are often physically impaired, and determining device preference and ease of use is vital. Objectivity: The aim of this human factors research was to compare migraine patients’ device use and preferences for three sumatriptan subcutaneous autoinjectors; a disposable two-step unit; and a multi-step reloadable device using simulated injections. The two-step unit had a first injection full-dose delivery success rate of 44. 4%, much higher than both the reloadable and three-step machines. The number of errors with the two-step unit was 90% lower than those with three-step and reloadable units. Conclusion: 54 migraineurs in this human factors research compared three sumatriptan subcutaneous delivery methods. Migraine patients favored the autoinjector, which they described as simpler and more convenient in this research.

Source link: https://doaj.org/article/619a40fa8f7e46eeb49e919d64cf8bef


Fabrication and characterisation of lavender oil - plant phospholipid based Sumatriptan succinate hybrid solid lipid nanoparticles.

Historical context: Sumatriptan succinate's nanostructured lipid carriers were created by using lavender oil. In ancient times, lavender oil was used for the treatment of a migraine. In a nano-formulation, the natural anti-migraine agent, lavender oil, mixed with an anti-migraine drug such as SS would provide a practical alternative to migraine therapy. Objective: Sumatriptan succinate's NLCs were produced by using LECIVA-S70, a natural anti-migraine oil that is a specialized grade for liposomal dermatological preparation and intended for emulsion, fat infusions, nutraceutical formulations, and parenteral use. Methods: To determine the relationship between independent variables and responses such as lavender oil and LECIVA-S70, a central composite design method was used. The in vitro drug release profile was determined by a membrane diffusion method. NLC's meanu00b1SD size varied from 411. 4 d. nm to 398. 8 d. nm, according to Nm's 398. 8 d. nm. The NLCs had a success with the lavender oil's unique fragrance.

Source link: https://doaj.org/article/508b32b11b0c4fd08a60f5e60d162034


Sumatriptan inhibits synaptic transmission in the rat midbrain periaqueductal grey

Abstract Background The midbrain periaqueductal grey has been implicated in migraines and the anti-migraine drug sumatriptan's behavior. In vitro, we investigated serotonergic modulation of GABAergic and glutamatergic synaptic transmission in rod midbrain PAG slices. Results Serotoninin and the selective serotonin reuptake inhibitor fluoxetine resulted in a decrease in the amplitude of GABA-evoked inhibitory currents in all PAG neurons, which was associated with an increase in the paired-pulse ratio of evoked IPSCs. In all PAG neurons tested, the amplitude of non-NMDA-mediated evoked excitation postsynaptic currents was reduced by 5-HT and sumatriptan. Conclusion These findings reveal that sumatriptan reduces GABAergic and glutamatergic synaptic transmission within the PAG by a 5-HT1B/D receptor-mediated reduction in the likelihood of neurotransmitter release from nerve terminals.

Source link: https://doi.org/10.1186/1744-8069-4-54


Cilostazol induced migraine does not respond to sumatriptan in a double blind trial

Cilostazol is an inhibitor of phosphodiesterase 3 and, as a result, cAMP accumulation occurs. It has never been investigated whether the cilostazol model responds to sumatriptan in migraine patients and, therefore, is safe for testing of new anti-migraine drugs. Methods In a cross-over research, 30 patients were treated cilostazol on two days each day and then prescribed placebo or sumatriptan 50 mg. We gathered headache characteristics and associated symptoms using a questionnaire. All participants suffered with headaches, although 19 patients on the placebo day met the requirements for a migraine-like attack; Cilostazol produced headaches with some migraine characteristics in some patients; 18 patients on the sumatriptan day and 19 patients on the placebo day met criteria for a migraine-like attack; At 2 h, the difference in median headache intensity between sumatriptan and placebo was not significant, but it was at 4 h. Conclusion The cilostazol model in migraine patients could not be backed up by a robust sumatriptan response.

Source link: https://doi.org/10.1186/s10194-018-0841-7

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions